Dataset Information

Thromboxane-A Synthase 1 as a Potential Dual Biomarker for Metastatic Prostate Cancer and Atherosclerosis: Insights from a Nanomedicine Protein Corona, Machine Learning, and Actual Causality Approaches

ABSTRACT: Prostate cancer (PC) is the most common cancer among men in the United States, while atherosclerosis (ASCVD) is the most prevalent cardiovascular disease (CVD) associated with it. CVD, particularly ASCVD, has been shown to contribute to metastatic prostate cancer (mPC) progression. Identifying blood-based biomarkers for these diseases is essential, yet current diagnostics face challenges in detecting low-abundance proteins in plasma. METHODS: This study introduces a nanomedicine platform that uses nanoparticle protein coronas, combined with mass spectrometry (MS)-based bottom up proteomics (BUP), machine learning, and actual causality analysis, to enable biomarker detection for ASCVD and mPC. Protein corona profiles were generated from 35 plasma samples divided into four groups: mPC with ASCVD, non-metastatic PC (nmPC) with ASCVD, mPC without ASCVD, and nmPC without ASCVD. BUP identified and quantified the proteins in the corona samples and discovered the differentially expressed proteins between different groups. LASSO (Least Absolute Shrinkage and Selection Operator) regularization within a logistic regression model was applied to determine proteins closely linked to ASCVD and mPC. Causality analysis then evaluated the proteins identified, focusing on those that could be considered causal factors in both ASCVD and mPC.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Cardiovascular System Disease,Prostate Cancer

SUBMITTER: Liangliang Sun

LAB HEAD: Liangliang Sun

PROVIDER: PXD057863 | Pride | 2025-11-21

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 107

Publications

AI-Driven Prediction of Cardio-Oncology Biomarkers Through Protein Corona Analysis.

Guha Avirup A Sadeghi Seyed Amirhossein SA Kunhiraman Harikrishnan Hyma HH Fang Fei F Wang Qianyi Q Rafieioskouei Arshia A Grumelot Shaun S Gharibi Hassan H Saei Amir Ata AA Sayadi Maryam M Weintraub Neal L NL Horibata Sachi S Yang Phillip Chung-Ming PC Bonakdarpour Borzoo B Ghassemi Mohammad M Sun Liangliang L Mahmoudi Morteza M

Chemical engineering journal (Lausanne, Switzerland : 1996) 20250301

Protein corona, a layer predominantly composed of proteins and other biomolecules that forms on nanoparticle surfaces upon interaction with biological fluids, has recently been extensively utilized to enhance the depth of plasma proteomics and biomarker discovery. In this study, we integrate protein corona profiling with mass spectrometry (MS)-based bottom-up proteomics (BUP), machine learning, and causality analysis to identify potential biomarkers in the field of cardio-oncology. We selected p ...[more]

PMID: 40190726

Similar Datasets

Project description:Metastatic clear cell renal cell carcinoma (ccRCC) has a poor prognosis and unpredictable course and there are no molecular markers that reliably predict ccRCC metastasis. In this study, specimens from 84 patients with ccRCC were directly cultured in vitro. The primary cultures from 38 of 94 specimens contained more than 90% tumor cells at 4th passages. After identified by immunostaining, the primary cultures of metastatic- and nonmetastatic ccRCC specimens from the age-, gender-matched patients were subjected to cDNA microrray assays. A total of 842 differentially expressed genes with FDR (false discovery rate) = 4.79% were identified by using SAM (Significance Analysis of Microarray) software. Pathway enrichment and co-occurrence with “cancer”, “metastasis” and “invasion” in the literature annotations enriched the functions of the 842 genes and indicated the reliability of our microarray assays. Novel genes associated with metastasis were selected based on intra-molecular interaction between 205 differentially expressed genes co-occurred with “metastasis” and those not appeared with “metastasis” on Medline, as well as co-expression analysis between 205 differentially expressed genes co-occurred with “metastasis” and those not appeared on Medline in 12 microarray data. FSTL1, AV722783, SLC15A1, DDX17, ORC2L and PKMYT1 were proved to be potential ccRCC metastasis-associated novel genes, based on its expression patterns in the cultures and tumor tissues. Interestingly, the up-regulated genes (CAV1, PKMYT1 and ORC2L) were up-regulated and the down-regulated genes (FSTL1, GSTM3, CYR61, SLC15A1 and AV722783) were down-regulated, in the primary ccRCC specimens as compared with its adjacent normal kidney in 37 patients (determined by semi-quantitative RT-PCR). This study provides potential biomarkers and novel molecular targets for the early diagnosis and treatment of ccRCC metastasis. Keywords: Homo sapiens Because of limited cell number of primary cultures, total RNA of the primary cultures from 2 age and gender matched patients was pooled for each microarray assay. Each assay was technically repeated once. Cy3-labeled 1st cDNA synthesized from total RNA of the metastatic ccRCC pool was mixed with Cy5-labeled 1st cDNA synthesized from total RNA of the non-metastatic ccRCC pool, and hybridized to 16K cDNA chips (GEO Platform ID: GPL6259; SBC-R-HC-100-22, National Engineering Center for Biochip, Shanghai, China) that included 14784 unigenes, 241 negative controls and 527 positive controls. In our study we used a co-expression analysis for the relationship between genes; three gastric cancer Samples were only introduced to this analysis methods.

Project description:Background: Colorectal cancer (CRC) is one of the major causes of cancer-related death worldwide. Although commercial biomarkers of CRC are currently available, they are still lacking in terms of sensitivity and specificity; thus, searching for reliable blood-based biomarkers are important for the primary screening of CRC. Methods: Plasma samples of patients with non-metastatic (NM) and metastatic (M) CRC and healthy controls were fractionated using MARS-14 immunoaffinity chromatography. The flow-through and elute fractions representing low- and high-abundant proteins, respectively, were analyzed by label-free quantitative proteomics mass spectrometry. The functional analysis of the proteins with greater than 1.5-fold differential expression level between the CRC and the healthy control groups were analyzed for their biological processes and molecular functions. In addition, the levels of plasma proteins showing large alterations in CRC patients were confirmed by immunoblotting using two independent cohorts. Moreover, receiver operating characteristic (ROC) curve analysis was performed for individual and combinations of biomarker candidates so as to evaluate the diagnostic performance of biomarker candidates. Results: From 163 refined identifications, five proteins were up-regulated and two proteins were down-regulated in NM-CRC while eight proteins were up-regulated and three proteins were down-regulated in M-CRC, respectively. Altered plasma proteins in NM-CRC were mainly involved in complement activation, while those in M-CRC were clustered in acute-phase response, complement activation, and inflammatory response. Results from the study- and validation-cohorts indicate that the levels of LRG, C9, AGP1, and A1AT were statistically increased, while FN level was statistically decreased in CRC patients compared to healthy controls, with most alterations found in a metastatic stage-dependent manner. ROC analysis revealed that FN exhibited the best diagnostic performance to discriminate CRC patients and healthy controls while AGP1 showed the best discrimination between the disease stages in both cohorts. The combined biomarker candidates, FN+A1AT+AGP1, exhibited perfect discriminatory power to discriminate between the CRC population and healthy controls whereas LRG+A1AT+AGP1 was likely to be the best panel to discriminate the metastatic stages in both cohorts. Conclusions: This study identified and quantified distinct plasma proteome profiles of CRC patients. Selected CRC biomarker candidates including FN, LRG, C9, A1AT, and AGP1 may be further applied for screening larger cohorts.

			Action	DRS
	090112024_S17_01.raw	Raw
	090112024_S17_02.raw	Raw
	090112024_S17_03.raw	Raw
	090112024_S18_01.raw	Raw
	090112024_S18_02.raw	Raw